Alga supplement could boost sight in rare eye disease
NCT ID NCT07509229
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a natural supplement from Dunaliella alga, rich in 9-cis beta-carotene, can improve vision in adults with retinitis pigmentosa. Forty-one participants will take the supplement or a placebo for 3 months, then switch after a 6-month break. Researchers will measure retinal sensitivity, electrical responses, and blood levels of vitamin A.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-cis beta-carotene-rich extract of Dunaliella alga (dietary supplement)
What this could lead to
If it works, this could point toward a natural supplement that slows vision loss or improves light sensitivity in retinitis pigmentosa.
What could go wrong
This is an early Phase 1/2 trial with only 41 people, so results may not apply broadly. The supplement may not improve vision and could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Goldschleger Eye Institute, Sheba Medical Center,
Tel Litwinsky, 52621, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••